AbbVie stock rose early Friday after the drug giant easily beat third-quarter forecasts with the help of its biggest drug, Skyrizi.
Yahoo
Skip to navigation
Skip to main content
Skip to right column
AbbVie's Earnings Double As Immunology Powerhouse Skyrizi Beats Again ·
Investor's Business Daily
